MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$13.7M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$12.9M |
| 3 |
Scholar Rock
SRRK
|
+$12.6M |
| 4 |
Guardant Health
GH
|
+$11.6M |
| 5 |
ALX Oncology
ALXO
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Geron
GERN
|
+$34.6M |
| 2 |
Viridian Therapeutics
VRDN
|
+$10.8M |
| 3 |
Amicus Therapeutics
FOLD
|
+$8.47M |
| 4 |
Sutro Biopharma
STRO
|
+$4.16M |
| 5 |
Viking Therapeutics
VKTX
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$728M
| $133M | 20.73% |
7,648,268
| – | – |
2021 Q1
13 quarters
|
|
2
Insmed
INSM
$25.1B
| $41.2M | 6.41% |
615,391
+84,597
| +16% | +$3.28M |
2022 Q4
6 quarters
|
|
3
Olema Pharmaceuticals
OLMA
$641M
| $28.7M | 4.46% |
2,654,867
+701,177
| +36% | +$7.6M |
2023 Q2
4 quarters
|
|
4
DELISTED
iTeos Therapeutics
ITOS
| $25.9M | 4.03% |
1,745,943
| – | – |
2020 Q3
15 quarters
|
|
5
DELISTED
Crinetics Pharmaceuticals
CRNX
| $25M | 3.88% |
557,184
+76,596
| +16% | +$3.54M |
2021 Q3
11 quarters
|
|
6
Madrigal Pharmaceuticals
MDGL
$9.28B
| $19.9M | 3.1% |
71,185
+9,786
| +16% | +$2.33M |
2022 Q2
8 quarters
|
|
7
Iovance Biotherapeutics
IOVA
$3.72B
| $19M | 2.95% |
2,366,714
+166,714
| +8% | +$1.79M |
2022 Q2
8 quarters
|
|
8
Natera
NTRA
$45B
| $18.9M | 2.94% |
174,811
+2,398
| +1% | +$244K |
2024 Q1
1 quarter
|
|
|
9
Mirum Pharmaceuticals
MIRM
$6.12B
| $16.8M | 2.62% |
+492,569
| New | +$12.9M |
2024 Q2
0 quarters
|
|
10
Ultragenyx Pharmaceutical
RARE
$1.57B
| $15.6M | 2.43% |
380,552
+134,962
| +55% | +$5.76M |
2024 Q1
1 quarter
|
|
11
MoonLake Immunotherapeutics
MLTX
$981M
| $15.1M | 2.35% |
343,235
+47,185
| +16% | +$2M |
2023 Q2
4 quarters
|
|
|
12
Guardant Health
GH
$20.4B
| $14.4M | 2.24% |
+500,000
| New | +$11.6M |
2024 Q2
0 quarters
|
|
13
Disc Medicine
IRON
$3.59B
| $13.8M | 2.14% |
305,658
+194,879
| +176% | +$6.62M |
2023 Q4
2 quarters
|
|
|
14
Alkermes
ALKS
$7.71B
| $13.4M | 2.09% |
+557,556
| New | +$13.7M |
2024 Q2
0 quarters
|
|
15
Edgewise Therapeutics
EWTX
$4.93B
| $13.3M | 2.07% |
740,661
+299,402
| +68% | +$5.22M |
2024 Q1
1 quarter
|
|
|
16
ALX Oncology
ALXO
$160M
| $13.2M | 2.04% |
2,180,864
+912,393
| +72% | +$11.2M |
2023 Q4
2 quarters
|
|
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $12.6M | 1.96% |
369,384
+44,051
| +14% | +$1.3M |
2023 Q3
3 quarters
|
|
18
Lantheus
LNTH
$6.58B
| $12M | 1.87% |
+150,000
| New | +$11M |
2024 Q2
0 quarters
|
|
19
Revolution Medicines
RVMD
$41.6B
| $11.2M | 1.75% |
289,396
+16,179
| +6% | +$605K |
2021 Q3
11 quarters
|
|
|
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
| $11M | 1.71% |
783,242
-87,907
| -10% | -$1.43M |
2023 Q2
4 quarters
|
|
21
Xeris Biopharma Holdings
XERS
$2.78B
| $10.9M | 1.69% |
4,830,526
+664,030
| +16% | +$1.34M |
2023 Q2
4 quarters
|
|
22
Axsome Therapeutics
AXSM
$6.96B
| $10.7M | 1.66% |
132,312
+18,185
| +16% | +$1.35M |
2022 Q4
6 quarters
|
|
23
DELISTED
KalVista Pharmaceuticals
KALV
| $10.4M | 1.61% |
881,937
+121,215
| +16% | +$1.41M |
2024 Q1
1 quarter
|
|
24
Intellia Therapeutics
NTLA
$1.59B
| $9.9M | 1.54% |
443,503
+10,905
| +3% | +$260K |
2021 Q3
11 quarters
|
|
25
DELISTED
HilleVax
HLVX
| $9.33M | 1.45% |
+645,085
| New | +$8.86M |
2024 Q2
0 quarters
|
|
Similar funds
MPM BioImpact's Q2 2024 Portfolio in Review
As of Q2 2024, MPM BioImpact held 47 positions worth $644M, up 3.5% from $622M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
MPM BioImpact deployed $87.7M of net new capital in Q2 2024, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Alkermes: 557,556 shares worth $13.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Sutro Biopharma, an estimated $4.16M trimmed.
- MPM BioImpact's largest Q2 2024 buy was Alkermes: 557,556 shares worth $13.4M.
- MPM BioImpact added most to ALX Oncology in Q2 2024, an estimated $11.2M increase.
- MPM BioImpact's biggest Q2 2024 reduction was Sutro Biopharma, cutting an estimated $4.16M.
- MPM BioImpact fully exited Geron in Q2 2024, selling an estimated $34.6M.
- MPM BioImpact's ten largest holdings make up 54% of its $644M portfolio in Q2 2024.
- MPM BioImpact opened 9 new positions and closed 3 in Q2 2024.
- MPM BioImpact's portfolio value rose 3.5% quarter-over-quarter to $644M.
Based on MPM BioImpact's 13F filing for Q2 2024, filed 14 Aug 2024.